Protecting the environment while growing our business

Ensuring continued care for patients

In the Philippines, many patients were affected by a lockdown so strict initially that there was no transport for them to get to their care. Therefore, Roche started with Flexcare transport, thanks to which we were able to get patients from wherever they were to their doctor, to their care.

Engaged people make the difference

At many locations, including Roche sites in California, New Jersey, Indiana and Switzerland, Roche Diagnostics emergency response teams have worked around the clock to produce and deliver the first commercial test to detect the novel coronavirus.

Beyond COVID-19—preventing cervical cancer

The WHO estimates that 311,000 women globally die each year from this disease, which is nearly 100% preventable with proper screening, vaccination and treatment.

Roche focuses on the science behind HPV, the known cause of almost all cases of cervical cancer, to help provide answers that aid clinical decision-making around patient care.

Hope for patients

A Roche cancer medicine paired with a Roche companion diagnostic test—and the powerful collaboration between the Roche Diagnostics’ and Roche Pharmaceuticals’ teams that delivered both to the market—have brought new hope to patients like Eva who are diagnosed with triple-negative breast cancer.

Telemedicine—digital pathology

The spread of COVID-19 has added an element of actual physical danger to the practice of pathology. With physicians and their staff at higher risk of exposure to the virus while on site at the hospital or laboratory, digital pathology that enables remote diagnoses has emerged as a vital technology.

Did you know?

SMA is a severe, progressive neuromuscular disease that can be fatal. It affects approximately one in 10,000 babies.

NMOSD is a rare and debilitating autoimmune condition of the CNS, causing blindness, muscle weakness and paralysis. It affects approximately 200,000 people worldwide.

Fingerprinting cancer

The insights from Comprehensive Genomic Profiling (CGP) help physicians refine their diagnosis, and provide prognostic information as well as predictive insights to each individual. This in turn allows physicians to match cancer-causing mutations with existing targeted therapies, rule out unnecessary therapies and thus personalise therapies.

Did you know?

When the availability of personalised care increases, both individual patients and society benefit. The Roche approach to personalised healthcare is rooted in a combination of advanced diagnostics, medicine, data, analytics, and digital technology, all with the goal of serving both patients and society at large.

Helping communities after disaster

Following the explosion in Beirut on 4 August 2020, we contributed to a broad spectrum of relief efforts across the country, supported emergency response and rebuilding initiatives, donated a Roche antibiotic to healthcare centres and replaced damaged diagnostic laboratory equipment.

A glimpse into the future

To succeed in Personalized Healthcare, this approach requires a holistic view of the entire healthcare delivery system. Prevention, diagnosis, treatment and monitoring—Roche approaches them as a comprehensive system of integrated healthcare solutions. Our goal is to reduce complexity while optimising therapy.